NPPB and hydrops fetalis: TDs were consistent in the low-risk group with median NT-proBNP 508 pg/mL [378–707], the intermediate-risk group with median NT-proBNP 1430 pg/mL [1216–1719], corresponding to a PARADIGM-HF cohort, and the high-risk group with median NT-proBNP 4740 pg/mL [3199–8397], corresponding to a typical cohort of patients treated with a ventricular assist device [21].